Risk factors for amenorrhea in juvenile systemic lupus erythematosus (JSLE): a Brazilian multicentre cohort study

Abstract

We evaluated the prevalence and clinical associations of amenorrhea in 298 female juvenile systemic lupus erythematosus (JSLE) patients (ACR criteria) followed in 12 Brazilian Paediatric Rheumatology centres. Amenorrhea was observed in 35 patients (11.7%) with a mean duration of 7.2 ± 3.6 months. The hormones were performed in 32/35 patients and none of them had FSH and LH levels above and estradiol below the normal range according to pubertal changes. JSLE patients with amenorrhea were younger (15.04 ± 2.5 versus 17.8 ± 3.1 years; P = 0.001), and had a shorter period of time between menarche and current age (3.4 ± 2.9 versus 6.7 ± 5.4 years; P = 0.001). Interestingly, the frequency, cumulative dose, number of pulses and duration of intravenous cyclophosphamide treatment were alike in patients with and without amenorrhea (P > 0.05). In contrast, patients with amenorrhea had significantly higher SLEDAI (P = 0.01) and SLICC/ACR-DI (P = 0.024) scores compared to those without this condition. Independent risk factors identified by multivariate analysis were higher SLEDAI (OR = 1.059; CI = 1.004—1.116; P = 0.034) and SLICC/ACR-DI (OR = 2.125; IC = 1.373—3.291; P = 0.001) scores. Our data suggest that in spite of immunosuppressive therapy, JSLE patients have an adequate ovarian follicular reserve and amenorrhea is particularly associated with disease activity and damage. Lupus (2007) 16, 531—536.

Keywords

adolescent amenorrhea cyclophosphamide gonadal function juvenile systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

Gurtcheff S. , Hatasaka H. Fertility and autoimmune disease. In Lock-shin M , Branch W eds. Handbook of systemic autoimmune disease. Reproductive and hormonal aspects of systemic autoimmune disease, Vol. 4. Elsevier, 2006; 29—42.

Schaller J. Lupus in childhood. Clin Rheum Dis 1982; 8:219—228.

Pasoto SG , Mendonca BB , Bonfa E. Menstrual disturbances in patients with systemic lupus erythematosus without alkylating therapy: clinical, hormonal and therapeutic associations. Lupus 2002; 11: 175—180.

Medeiros MM , Silveira VA , Menezes AP , Carvalho RC Risk factors for ovarian failure in patients with systemic lupus erythematosus . Braz J Med Biol Res 2001; 34: 1561—1568.

Metcalf MG , Skidmore D. , Lowry GF , Mackenzie JA Incidence of ovulation in the years after the menarche. J Endocrinol 1983; 97: 213—219.

Park MC , Park YB , Jung SY , Chung IH , Choi KH , Lee SK Risk of ovarian failure and pregnancy outcome in patients with lupus nephritis treated with intravenous cyclophosphamide pulse therapy. Lupus 2004; 13: 569—574.

Pasoto SG , Viana VS , Mendonca BB , Yoshinari NH , Bonfa E. Anti-corpus luteum antibody: a novel serological marker for ovarian dysfunction in systemic lupus erythematosus?. J Rheumatol 1999; 26: 1087—1093.

Boumpas DT , Austin HA , Vaughan EM , Yarboro CH , Klippel JH , Balow JE Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med 1993; 119: 366—369.

Wang CL , Wang F. , Bosco JJ Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus . Lupus 1995; 4: 11—14.

10.

McDermott EM , Powell RJ Incidence of ovarian failure in systemic lupus erythematosus after treatment with pulse cyclophosphamide. Ann Rheum Dis 1996; 55: 224—229.

11.

Mok CC , Lau CS , Wong RW Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998; 41: 831—837.

12.

Ioannidis JP , Katsifis GE , Tzioufas AG , Moutsopoulos HM Predictors of sustained amenorrhea from pulsed intravenous cyclophosphamide in premenopausal women with systemic lupus erythematosus. J Rheumatol 2002; 29: 2129—2135.

13.

Huong du L. , Amoura Z. , Duhaut P. et al. Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 2002; 29: 2571—2576.

14.

Silva CA , Leal MM , Simone VP et al. Gonadal function in adolescents and young female with systemic lupus erythematosus. Lupus 2002; 11: 419—425.

15.

Gonzalez-Crespo MR , Gomez-Reino JJ , Merino R. et al. Menstrual disorders in girls with systemic lupus erythematosus treated with cyclophosphamide. Br J Rheumatol 1995; 34: 737—741.

16.

Brunner HI , Silverman ED , To T. , Bombardier C. , Feldman BM Risk factors for damage in childhood-onset systemic lupus erythematosus: cumulative disease activity and medication use predict disease damage. Arthritis Rheum 2002; 46: 436—444.

17.

Brunner HI , Bishnoi A. , Barron AC et al. Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus. Lupus 2006; 15: 198—206.

18.

Ravelli A. , Duarte-Salazar C. , Buratti S. et al. Assessment of damage in juvenile-onset systemic lupus erythematosus: a multicenter cohort study. Arthritis Rheum 2003; 49: 501—507.

19.

Hochberg MC Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthrits Rheum 1997; 40: 1725.

20.

Niaudet P. Treatment of lupus nephritis in children. Pediatric Nephrology 2000; 14: 158—166.

21.

Bombardier C. , Gladman DD , Urowitz MB , Karon D. , Chang CH and The Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 630—640.

22.

Brunner HI , Silverman ED , To T. , Bombardier C. , Feldman BM Sensitivity of the Systemic Lupus Erytematosus Disease Activity Index, British Isles Lupus Assessement Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erytematosus . Arthrits Rheum 1999; 42: 1354—1360.

23.

Gladman D. , Ginzler E. , Goldsmith C. et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/ American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363—369.

24.

Bernatsky S. , Boivin JF , Joseph L. et al. Mortality in systemic lupus erythematosus . Arthritis Rheum 2006; 54: 2550—2557.

25.

Kim YK , Wasser SK , Fujimoto VY , Klein NA , Moore DE , Soules MR Utility of follicle stimulating hormone (FSH), luteinizing hormone (LH), oestradiol and FSH:LH ratio in predicting reproductive age in normal women. Hum Reprod 1997; 12: 1152—1155.

26.

de Medeiros SF , Assi PE , de Medeiros MM. Gonadotrophin dynamics during reproductive life. Int J Gynaecol Obstet 2004; 87: 24—28.